{"id":"novorapid-penfill","safety":{"commonSideEffects":[{"rate":null,"effect":"Hypoglycemia"},{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Weight gain"},{"rate":null,"effect":"Lipodystrophy"}]},"_chembl":{"chemblId":"CHEMBL1201496","moleculeType":"Protein"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"NovoRapid (insulin aspart) is a recombinant human insulin analog with a rapid onset of action, typically beginning to work within 10-20 minutes of injection. It mimics the body's natural insulin response to meals by binding to insulin receptors on muscle and fat cells, promoting glucose uptake and storage while inhibiting hepatic glucose production. This rapid action makes it suitable for mealtime insulin therapy in diabetes management.","oneSentence":"NovoRapid is a rapid-acting insulin analog that binds to insulin receptors to facilitate glucose uptake and utilization in cells.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:50:28.981Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 1 diabetes mellitus"},{"name":"Type 2 diabetes mellitus"}]},"trialDetails":[{"nctId":"NCT05221580","phase":"","title":"China Research of IDEgAsp Treatment in Real-world Clinical practicE (CREATE)","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2022-03-18","conditions":"Diabetes Mellitus, Type 2","enrollment":887},{"nctId":"NCT04079413","phase":"PHASE3","title":"Efficacy and Safety of GP40071 Compared to NovoRapid® Penfill® in Type 1 Diabetes Mellitus Patients","status":"COMPLETED","sponsor":"Geropharm","startDate":"2019-06-03","conditions":"Diabetes, Diabetes Mellitus, Type 1","enrollment":264},{"nctId":"NCT04184466","phase":"NA","title":"A Study to Compare Pharmacokinetics and Pharmacodynamics of Insulin Aspart to NovoRapid® Penfill® in Healthy Subjects","status":"COMPLETED","sponsor":"Geropharm","startDate":"2018-10-18","conditions":"Clamp Study","enrollment":26},{"nctId":"NCT04184492","phase":"NA","title":"A Study to Compare Pharmacokinetics and Pharmacodynamics of GP-40081 to NovoMix® 30 Penfill® in Healthy Subjects","status":"COMPLETED","sponsor":"Geropharm","startDate":"2019-04-15","conditions":"Clamp Study","enrollment":34},{"nctId":"NCT02590016","phase":"PHASE4","title":"Glucose Control During Labour in Gestational Diabetes Mellitus With Insulin Treatment: A Randomized Controlled Trial","status":"UNKNOWN","sponsor":"Tampere University Hospital","startDate":"2015-09","conditions":"Gestational Diabetes, Hypoglycemia, Neonatal","enrollment":50},{"nctId":"NCT03374774","phase":"","title":"A Non-interventional Study of Ability and Willingness to Pay for BIAsp 30 in a Real World Population With Type 2 Diabetes Mellitus (T2DM)","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2017-11-13","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":516},{"nctId":"NCT02219750","phase":"PHASE4","title":"Comparison of Premixed Insulin With Basal-plus Insulin in Type 2 Diabetes Patients","status":"COMPLETED","sponsor":"Mackay Memorial Hospital","startDate":"2013-08","conditions":"Diabetes","enrollment":181},{"nctId":"NCT01490112","phase":"","title":"Surveillance Study of NovoRapid® for New Drug Re-examination","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2005-01","conditions":"Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2","enrollment":1239}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":9,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["insulin aspart","Insulin aspart"],"phase":"phase_3","status":"active","brandName":"NovoRapid® Penfill®","genericName":"NovoRapid® Penfill®","companyName":"Geropharm","companyId":"geropharm","modality":"Small molecule","firstApprovalDate":"","aiSummary":"NovoRapid is a rapid-acting insulin analog that binds to insulin receptors to facilitate glucose uptake and utilization in cells. Used for Type 1 diabetes mellitus, Type 2 diabetes mellitus.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}